MD, PhD, FRCP
Emeritus Associate Professor
I qualified as a doctor at Charing Cross Hospital Medical School and trained in Medical Oncology at the Royal Marsden Hospital London and Churchill Hospital Oxford. Following a PhD with Alan Ashworth at Chester Beatty Laboratories in London, my postdoctoral training was supported by MRC Clinician Scientist and Cancer Research UK Senior Clinical Fellowships and HEFCE Clinical Senior Lectureship. I was Associate Professor and Honorary Consultant in Medical Oncology, Department of Oncology, University of Oxford from 2001 to 2021, now Emeritus Associate Professor, Nuffield Department of Surgical Sciences, University of Oxford. My laboratory research group uses basic, translational and clinical research to investigate the role of IGFs in prostate cancer and is supported by collaborating clinicians and scientists in Oxford and elsewhere.
Targeting IGF perturbs global replication through ribonucleotide reductase dysfunction.
Rieunier G. et al, (2021), Cancer Res
IGF targeting perturbs global replication through ribonucleotide reductase dysfunction.
RIEUNIER G. et al, (2020), BioRxiv
CHK1 inhibition exacerbates replication stress induced by IGF blockade.
WU X. et al, (2020), TBC
Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma.
Simpson AD. et al, (2020), Br J Cancer, 122, 624 - 629
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
Gupta A. et al, (2020), Br J Cancer, 122, 506 - 516